MRgLITT for mTLE: A PROBE Trial
MINE
Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Mesial Temporal Lobe Epilepsy: A Prospective, Randomized, Open Blinded, End-point Trial
1 other identifier
interventional
120
1 country
1
Brief Summary
How does magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) impact clinical prognosis in mesial temporal lobe epilepsy (mTLE)?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 3, 2024
CompletedFirst Posted
Study publicly available on registry
December 6, 2024
CompletedStudy Start
First participant enrolled
July 21, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2028
January 21, 2026
July 1, 2025
1.4 years
December 3, 2024
January 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Seizure freedom rate
According to International League Against Epilepsy \[ILAE\] Outcome Scale
6-month, 1-year after surgery
Secondary Outcomes (10)
Seizure frequency
6-month, 1-year after surgery
Seizure severity
6-month, 1-year after surgery
Cognitive function evaluation
6-month, 1-year after surgery
Memory function evaluation
6-month, 1-year after surgery
Quality of life for epilepsy patients
6-month, 1-year after surgery
- +5 more secondary outcomes
Study Arms (2)
Open Surgery (anterior temporal lobectomy, ATL)
EXPERIMENTALMinimally Invasive Surgery (MRgLITT)
ACTIVE COMPARATORInterventions
MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
Eligibility Criteria
You may qualify if:
- years.
- Drug-resistant mesial temporal lobe epilepsy.
- Seizure frequency ≥ 1 time /month.
- Participants approved.
You may not qualify if:
- History of brain surgery.
- Intracranial space occupying lesions.
- Individuals with significant medical comorbidities or conditions that pose an excessive risk for surgery, such as severe cardiovascular disease, respiratory disorders, or uncontrolled systemic infections.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070, China
Related Publications (1)
Mo J, Guo Z, Wang X, Zhang J, Hu W, Shao X, Sang L, Zheng Z, Zhang C, Zhang K. Magnetic resonance-guided laser interstitial thermal therapy vs. open surgery for drug-resistant mesial temporal lobe epilepsy: a propensity score matched retrospective cohort study. Int J Surg. 2024 Jan 1;110(1):306-314. doi: 10.1097/JS9.0000000000000811.
PMID: 37800596BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr.
Study Record Dates
First Submitted
December 3, 2024
First Posted
December 6, 2024
Study Start
July 21, 2025
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2028
Last Updated
January 21, 2026
Record last verified: 2025-07